United States Pharmaceuticals

Organon & Co (OGN)

Track

Over the past 90 days, Organon & Co. recorded two insider transactions totaling approximately $400,614 in sales. These transactions involved Juliana Papa Drinane, Head of Manufacturing and Supply. The stock is currently trading near its 52-week high, following a recent earnings report that showed an EPS miss of 5.88%.
Ticker: OGN Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Organon & Co. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 5 Aug 2026
Value US$3,483,919.01 | Price 479.63 | Shares 42,306
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-05 2026-08-05 PrS Proposed sale
JULIANA P DRINANE

Officer

Officer
42,306
479.63
US$3,483,919 		42,306 479.63 US$3,483,919
2026-08-05 2026-08-05 S Sale
Drinane Juliana Papa

Head of Mfg & Supply

Officer
8,245 +43.3%
183.48
US$4,755,850 		8,245 +43.3% 183.48 US$4,755,850
2026-05-08 2026-05-06 PrS Proposed sale
Holzbaur Lynette

Affiliate
67,804
357.42
US$3,474,032 		67,804 357.42 US$3,474,032
2026-05-07 2026-05-06 B Purchase
Holzbaur Lynette

SVP and Corporate Controller

Officer
26,448 +100.2%
13.35
US$353,080 		26,448 +100.2% 13.35 US$353,080
2025-11-13 2025-11-12 B Purchase
2.7
COX CARRIE SMITH

Executive Chair

Executive Director
65,400 +524.5%
7.67
US$501,755 		65,400 +524.5% 7.67 US$501,755
2025-05-15 2025-05-14 B Purchase
2.7
COX CARRIE SMITH
Non-Executive Director
12,469 +inf%
8.07
US$100,591 		12,469 +inf% 8.07 US$100,591
2025-05-07 2025-05-07 B Purchase
2.4
Falcione Aaron

Chief Human Resources Officer

Officer
5,500 +9.6%
8.77
US$48,235 		5,500 +9.6% 8.77 US$48,235
2025-05-07 2025-05-06 B Purchase
3.1
Weaver Kirke

Gen. Counsel & Corp. Secy.

Officer
8,045 +18.1%
9.21
US$74,054 		8,045 +18.1% 9.21 US$74,054
2025-05-07 2025-05-06 B Purchase
3.1
Karp Daniel

Executive VP, Corp. Dev.

Officer
3,500 +8.1%
8.24
US$28,828 		3,500 +8.1% 8.24 US$28,828
2025-05-06 2025-05-05 B Purchase
1.8
WALSH MATTHEW M

Chief Financial Officer

Officer
11,400 +8.6%
8.82
US$100,548 		11,400 +8.6% 8.82 US$100,548
2025-05-06 2025-05-05 B Purchase
2.9
Ali Kevin

Chief Executive Officer

Executive Director
34,000 +13.7%
8.81
US$299,370 		34,000 +13.7% 8.81 US$299,370
2024-02-23 2024-02-22 B Purchase
3.1
Weaver Kirke

Gen. Counsel & Corp. Secy.

Officer
2,720 +21.8%
18.36
US$49,939 		2,720 +21.8% 18.36 US$49,939
Explore more

More insider trading research around Organon & Co

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America